Want to see DYN full AI Analyst Report?
Top Page
Dyne Therapeutics
(NASDAQ:DYN)
Select Model
Select Model
Rating:57Neutral
Price Target:
$24.50
▲(20.04% Upside)
Action:Reiterated
Date:07/20/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and significant cash burn), despite a low-debt balance sheet. Offsetting this are strong technical uptrend signals and positive corporate catalysts, especially the FDA Priority Review for DYNE-251, which improves the outlook for a potential transition toward commercialization.
Positive Factors
FORCE platform
Dyne’s FORCE delivery platform is a durable scientific asset enabling targeted payload delivery to muscle. Platform-driven programs can create multiple asset opportunities, attract partners and licensing deals, and provide structural competitive advantage across neuromuscular indications beyond any single program.
Negative Factors
No revenue; widening losses
Dyne is pre‑commercial with no product revenue and materially widening net losses. Persistent negative operating leverage means the company cannot self-fund its growth today; absent program approvals or large partnerships, sustained losses increase dependence on external financing over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
FORCE platform
Dyne’s FORCE delivery platform is a durable scientific asset enabling targeted payload delivery to muscle. Platform-driven programs can create multiple asset opportunities, attract partners and licensing deals, and provide structural competitive advantage across neuromuscular indications beyond any single program.
Read all positive factors
Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.92B
Dividend YieldN/A
Average Volume (3M)2.12M
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue GrowthN/A
EPS Growth10.17%
CountryUS
Employees263
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.22
Shares Outstanding165,313,800
10 Day Avg. Volume2,039,199
30 Day Avg. Volume2,122,427
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.33Price Target Upside97.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.09
Revenue Forecast (FY)N/A
Dyne Therapeutics Business Overview & Revenue Model
Company Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, ...
How the Company Makes Money
Dyne Therapeutics primarily makes money through a mix of (1) collaboration/partnering revenue and (2) financing, because it is a clinical-stage company without broadly marketed commercial products.
1) Collaboration and partnership revenue: When D...
Dyne Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.07M | -2.05M | -2.24M | -2.46M | 0.00 | 0.00 |
| EBITDA | -432.20M | -437.97M | -315.18M | -233.48M | -163.50M | -148.20M |
| Net Income | -451.71M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
Balance Sheet | ||||||
| Total Assets | 1.08B | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M |
| Cash, Cash Equivalents and Short-Term Investments | 972.16M | 1.11B | 642.27M | 123.10M | 256.01M | 376.57M |
| Total Debt | 19.30M | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M |
| Total Liabilities | 214.90M | 214.83M | 61.40M | 73.79M | 53.96M | 57.47M |
| Stockholders Equity | 865.05M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
Cash Flow | ||||||
| Free Cash Flow | -462.19M | -405.13M | -294.75M | -188.89M | -156.71M | -123.18M |
| Operating Cash Flow | -442.24M | -403.21M | -292.37M | -188.16M | -153.65M | -119.56M |
| Investing Cash Flow | -32.60M | -28.75M | -204.08M | 83.31M | 87.20M | -137.89M |
| Financing Cash Flow | 756.13M | 890.31M | 809.89M | 54.32M | 37.39M | 157.82M |
Dyne Therapeutics Technical Analysis
Positive
20.41
Price Trends
19.79
Positive
18.90
Positive
18.60
Positive
Market Momentum
1.18
Positive
60.53
Neutral
59.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Positive. The current price of 20.41 is below the 20-day moving average (MA) of 22.54, above the 50-day MA of 19.79, and above the 200-day MA of 18.60, indicating a bullish trend. The MACD of 1.18 indicates Positive momentum. The RSI at 60.53 is Neutral, neither overbought nor oversold. The STOCH value of 59.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYN.
Dyne Therapeutics Risk Analysis
Dyne Therapeutics disclosed 83 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dyne Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $3.56B | -1,433.85 | -1.41% | ― | 95.29% | 98.21% | |
61 Neutral | $1.78B | -90.95 | -4.83% | ― | 23.64% | ― | |
57 Neutral | $3.92B | -7.28 | -58.28% | ― | ― | 10.17% | |
54 Neutral | $1.82B | 27.15 | 4.89% | ― | -2.20% | 77.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $2.83B | ― | -5.89% | ― | 157.97% | 86.11% | |
45 Neutral | $6.68B | -12.44 | -83.29% | ― | ― | 0.01% |
* Healthcare Sector Average
DYN
Dyne Therapeutics
23.45
14.24
154.61%
SRPT
Sarepta Therapeutics
16.83
3.21
23.61%
COGT
Cogent Biosciences
38.30
25.85
207.63%
ARQT
Arcutis Biotherapeutics
27.53
12.98
89.21%
BEAM
Beam Therapeutics
26.33
4.79
22.24%
IMCR
Immunocore Holdings
34.05
-3.10
-8.34%
Dyne Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Dyne Therapeutics Advances DYNE-251 With FDA Priority Review
Positive
Jul 20, 2026
On July 20, 2026, Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (DYNE-251) to treat individuals with Duchenne muscular dystrophy am...
Executive/Board Changes
Dyne Therapeutics Names Barry Greene Independent Board Director
Positive
Jun 22, 2026
On June 22, 2026, Dyne Therapeutics, Inc. appointed Barry E. Greene as a Class I independent director to its board, with a term extending until the 2027 Annual Meeting of Stockholders and continuation subject to standard conditions such as death, ...
Business Operations and StrategyPrivate Placements and Financing
Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
Positive
Jun 17, 2026
On June 16, 2026, Dyne Therapeutics entered into a second amendment to its loan and security agreement with Hercules Capital and other lenders, expanding its debt facility to up to $400 million and relaxing certain financial covenants. The amendme...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
Positive
Jun 8, 2026
On June 5, 2026, Dyne Therapeutics, Inc. held its 2026 annual meeting of stockholders, where shareholders elected David Lubner, Brian Posner and Jason Rhodes as Class III directors for terms expiring at the 2029 annual meeting. Investors also appr...
Business Operations and StrategyProduct-Related Announcements
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy
Positive
Jun 3, 2026
On June 3, 2026, Dyne Therapeutics announced it has fully enrolled 71 participants in the registrational expansion cohort of its global Phase 1/2 ACHIEVE trial of zeleciment basivarsen in myotonic dystrophy type 1. The trial, which selected a regi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.